An open-label randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer patients following prior anthracycline and taxane therapy

Trial Profile

An open-label randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer patients following prior anthracycline and taxane therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Indisulam (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 06 Mar 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 27 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top